Cytotoxic flavonoids and isoflavonoids from Erythrina sigmoidea towards multi-factorial drug resistant cancer cells Victor KueteLouis P. SandjoThomas Efferth PRECLINICAL STUDIES 19 July 2014 Pages: 1053 - 1062
Improved replication efficiency of echovirus 5 after transfection of colon cancer cells using an authentic 5’ RNA genome end methodology S. IsraelssonA. SävnebyA. M. Lindberg PRECLINICAL STUDIES 23 July 2014 Pages: 1063 - 1070
Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities Dawn N. WaterhouseBrent W. SutherlandMurray S. Webb PRECLINICAL STUDIES Open access 27 July 2014 Pages: 1071 - 1082
“Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183” Serena MarchettiDick PluimJan H. M. Schellens PRECLINICAL STUDIES 31 July 2014 Pages: 1083 - 1095
Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells Nicole GrabinskiFlorian Ewald PRECLINICAL STUDIES 01 August 2014 Pages: 1096 - 1104
CG100649, a novel COX-2 inhibitor, inhibits colorectal adenoma and carcinoma growth in mouse models Sun-Hee KimOfer MargalitRaymond N. DuBois PRECLINICAL STUDIES 03 August 2014 Pages: 1105 - 1112
Ellipticine derivative induces potent cytostatic effect in acute myeloid leukaemia cells E. G. RussellE. C. O’SullivanT. G. Cotter PRECLINICAL STUDIES 10 August 2014 Pages: 1113 - 1122
A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer Silvia ValtortaGabriella NicoliniPaola Coccetti PRECLINICAL STUDIES 19 August 2014 Pages: 1123 - 1133
In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA Dexin KongTakao YamoriShingo Dan PRECLINICAL STUDIES 26 August 2014 Pages: 1134 - 1143
Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors Florian EwaldDominik NörzManfred Jücker PRECLINICAL STUDIES 26 August 2014 Pages: 1144 - 1154
AD-O53.2—a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L Jerzy S. PieczykolanKonrad KubińskiRafał Zieliński PRECLINICAL STUDIES 04 September 2014 Pages: 1155 - 1166
Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance Valeria SeroElisa TavantiMassimo Serra PRECLINICAL STUDIES 07 September 2014 Pages: 1167 - 1180
Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study Gerald FalchookRazelle KurzrockSunil Sharma PHASE I STUDIES 01 June 2014 Pages: 1181 - 1187
Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors Rastislav BahledaCristiana SessaJean-Charles Soria PHASE I STUDIES 06 June 2014 Pages: 1188 - 1196
A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck Daniel W. BowlesNeil SenzerAntonio Jimeno PHASE I STUDIES 12 June 2014 Pages: 1197 - 1203
First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors D. S. HongH. HenaryR. Kurzrock PHASE I STUDIES 13 June 2014 Pages: 1204 - 1212
Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients Ajay K. GopalStefano R. TarantoloAndre Goy PHASE I STUDIES 15 June 2014 Pages: 1213 - 1225
A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors Quincy S. ChuRandeep SanghaHal W. Hirte PHASE I STUDIES 19 July 2014 Pages: 1226 - 1235
Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors A. Craig LockhartShankar SundaramAlain C. Mita PHASE I STUDIES 13 August 2014 Pages: 1236 - 1245
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma Nizar M. TannirAndres Forero-TorresJohn A. Thompson PHASE I STUDIES 22 August 2014 Pages: 1246 - 1257
An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer Roberto PiliMichael CarducciHerbert Hurwitz PHASE I STUDIES Open access 26 August 2014 Pages: 1258 - 1268
A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin Irene BranaAlberto OcanaPhilippe L. Bedard PHASE I STUDIES 12 September 2014 Pages: 1269 - 1277
Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) A. RuzsaM. SenNA EMD 1201081 Study Group PHASE II STUDIES 04 June 2014 Pages: 1278 - 1284
A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer Meng ZhaoXueliang PanBhuvaneswari Ramaswamy PHASE II STUDIES 05 June 2014 Pages: 1285 - 1294
The efficacy of Pistacia Terebinthus soap in the treatment of cetuximab-induced skin toxicity Didem TastekinMakbule TambasDeniz Arslan PHASE II STUDIES 15 June 2014 Pages: 1295 - 1300
Human uridine phosphorylase-1 inhibitors: a new approach to ameliorate 5-fluorouracil-induced intestinal mucositis Daiana RenckAndré A. Santos JrLuiz A. Basso SHORT REPORT 23 July 2014 Pages: 1301 - 1307
Pneumocystis jirovecii pneumonia under everolimus in two patients with metastatic pancreatic neuroendocrine tumors Mélodie CarbonnauxYann MolinThomas Walter SHORT REPORT 14 August 2014 Pages: 1308 - 1310
Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors Hyun Sun WooHee Kyung AhnEun Kyung Cho SHORT REPORT 23 August 2014 Pages: 1311 - 1315
Contributions from emerging transcriptomics technologies and computational strategies for drug discovery Onat KadiogluThomas Efferth REVIEW 16 March 2014 Pages: 1316 - 1319